Trials / Completed
CompletedNCT04811651
Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke
Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke (UMSIS): a Prospective, Double-blinded, Randomized Controlled, Pilot Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 156 (actual)
- Sponsor
- General Hospital of Shenyang Military Region · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a doble blind, placebo controlled clinical trial to assess safety and efficacy of intravenous administration of Umbilical cord-derived Mesenchymal Stem cells in patients with ischemic stroke within 6 months of onset.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Umbilical Cord-derived Mesenchymal Stem Cells | umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million. |
| DRUG | Placebo | intravenous placebo solution with the same appearance as the treatment group. |
Timeline
- Start date
- 2021-03-15
- Primary completion
- 2024-07-30
- Completion
- 2024-07-30
- First posted
- 2021-03-23
- Last updated
- 2024-09-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04811651. Inclusion in this directory is not an endorsement.